OVERVIEW
Happy Saturday

Welcome to the Stocktwits Top 25 Newsletter this week!

The Stocktwits Top 25 reports the 25 best-performing stocks in the S&P 500, Nasdaq 100, and Russell 2000 year to date and tracks their performances over time. To help you understand this data further, check out our FAQ page, and feel free to reach out if you have questions!

Here are the Stocktwits Top 25 Lists for this week:

S&P 500
ST Top 25 S&P 500 💪

SPONSORED BY TRADR ETFS
With SpaceX Finally Public, Choose Your Mission with Two Leveraged ETFs

Few companies have generated as much excitement, debate and anticipation as SpaceX (SPCX).

Supporters see a company that transformed the economics of space launch, built one of the largest satellite networks, and sits at the intersection of aerospace, AI, and communications. Skeptics question the valuation, the ambitious projects, and whether expectations have gotten ahead of reality.

Whatever your view, Tradr ETFs launched two leveraged ETFs designed for active traders who want amplified exposure to the daily moves of SPCX.

For bulls, the Tradr 2X Long SpaceX Daily ETF (Cboe: SPCM) seeks to deliver 200% of the daily performance of SpaceX stock. For bears, the Tradr 2X Short SpaceX Daily ETF (Cboe: SPCG) seeks to deliver -200% of the daily performance of SpaceX stock.

The mission is yours to choose.

Investing in leveraged ETFs involves significant risk. For details, see www.tradretfs.com.

*3rd Party Ad. Not an offer or recommendation by Stocktwits. See disclosure here.

NASDAQ 100
The Large-Cap Nasdaq 100 🤖

RUSSELL 2000
The Growth-Centric Russell 2000 🦐

New This Week: LOUD NAMES
Top Momentum Movers Ranked By Watcher and Sentiment on Stocktwits

Mid-Cap / Micro-Cap Top Movers of the Week 🐶

📋 Small-Cap Watchlist

Biotech binaries dominated this week’s Russell momentum screen, with one AI storage contract crashing the party.

$TNGX ( ▲ 4.41% )  : Tango Therapeutics, $4.9B cap, jumped 10 spots to #15: This week’s top dawg held a +255% YTD move after June 8 Phase 1/2 pancreatic cancer data showed a 92% response rate. Risk: the readout was tiny, uncontrolled, and followed by a $500M offering.

$NVCT ( ▼ 2.44% )  : Nuvectis Pharma, $739M cap, new at #14: Nuvectis posted the screen’s biggest WTD move at +97% after a June 22 Haisco license deal added two clinical-stage compounds. Risk: the deal requires financing conditions, so dilution risk is not theoretical.

$DFTX ( ▲ 0.36% )  : Definium Therapeutics, $4.9B cap, new at #16: Definium added +84% WTD after Phase 3 DT120-ODT depression data beat placebo by 8.1 points at six weeks. Risk: FDA review, DEA scheduling, and six-hour monitored dosing make this a regulatory binary.

$BLZE ( ▲ 8.5% )  : Backblaze, $807M cap, new at #23: Backblaze ripped +78% WTD after a $335M, five-year CoreWeave storage deal that dwarfs its 2025 cloud storage base. Risk: one giant customer contract can become one giant execution test.

$SLS ( ▲ 17.66% )  : SELLAS Life Sciences, $2.3B cap, new at #18: SELLAS rose +54% WTD as the Phase 3 REGAL AML trial closed in on its 80-event final analysis, with 78 events reached as of May 11. Risk: this is a binary survival readout, and a $150M ATM is available.

Next week’s swing factor: Monday, June 29, is the first session with the reconstituted Russell indexes live. Fresh index flows can validate the new entrants or expose the crowded biotech chase.

Get In Touch 📬

Help us deliver the best content possible by completing this brief survey. 📝

Want to see some change? Email Kevin Travers your feedback; follow him on Stocktwits.

Terms & Conditions 📝

Securities Disclaimer: STOCKTWITS IS NOT A TAX ADVISOR, BROKER, FINANCIAL ADVISOR OR INVESTMENT ADVISOR. THE SERVICE IS NOT INTENDED TO PROVIDE TAX, LEGAL, FINANCIAL OR INVESTMENT ADVICE, AND NOTHING ON THE SERVICE SHOULD BE CONSTRUED AS AN OFFER TO SELL, A SOLICITATION OF AN OFFER TO BUY, OR A RECOMMENDATION FOR ANY SECURITY. Trading in such securities can result in immediate and substantial losses of the capital invested. You should only invest risk capital, and not capital required for other purposes. You alone are solely responsible for determining whether any investment, security or strategy, or any other product or service, is appropriate or suitable for you based on your investment objectives and personal and financial situation. You should also consult an attorney or tax professional regarding your specific legal or tax situation. The Content is to be used for informational and entertainment purposes only and the Service does not provide investment advice for any individual. Stocktwits, its affiliates and partners specifically disclaim any and all liability or loss arising out of any action taken in reliance on Content, including but not limited to market value or other loss on the sale or purchase of any company, property, product, service, security, instrument, or any other matter. You understand that an investment in any security is subject to a number of risks, and that discussions of any security published on the Service will not contain a list or description of relevant risk factors. In addition, please note that some of the stocks about which Content is published on the Service have a low market capitalization and/or insufficient public float. Such stocks are subject to more risk than stocks of larger companies, including greater volatility, lower liquidity and less publicly available information. Read the full terms & conditions here. 🔍

Author Disclosure: The author of this newsletter does not hold positions in any of the securities or assets mentioned. 📋